James O. Kahn, MD is an Associate Professor of Medicine at the University of California, San Francisco (UCSF), Associate Director of the Positive Health Program (PHP) (formally known as the AIDS Program) at San Francisco General Hospital (SFGH) and Associate Director of the UCSF-Gladstone Institute of Virology and Immunology's Center for AIDS Research (CFAR). Additionally, Dr. Kahn is the former chair of the Committee for Human Research at UCSF. He has completed fellowship training in medical oncology and clinical epidemiology, with an emphasis on research methods. With support from a 3-year Career Development Award from the American Cancer Society, Dr. Kahn attained the experience and skills necessary to become an independent investigator and to build a multidisciplinary research team in patient-oriented research. Dr. Kahn has developed an international reputation as a clinical trialist in patient-oriented HIV/AIDS research, with expertise in the areas of antiretroviral drug development, HIV-1 vaccine development, primary HIV-1 infection and prevention of HIV infection. Dr. Kahn has also been a very active mentor for beginning clinical investigators from diverse backgrounds, including younger physicians on faculty in the PHP, as well as visiting fellows from other countries. All junior faculty supported and mentored by Dr. Kahn are active in patient-oriented research. K-24 support will enable Dr. Kahn to achieve his long-term career goal of establishing a clinical research program that will: (1) integrate a multidisciplinary approach to prevention of HIV-1 infection; (2) conduct exploratory clinical research on the determinants of HIV-1 transmission; (3) include a comprehensive mentoring program for HIV/AIDS clinical investigators; and (4) create a clinical outcomes research agenda that focuses on the clinical effectiveness of HIV care in primary care settings. An initial research focus will be an assessment of the impact of current clinical practice guidelines on the primary medical care of HIV- infected adults, and the long-term virologic, immunologic and clinical outcomes in this population. Data for this prospective, observational cohort will be collected with the use of HIVWatch, a web-based, electronic medical record system developed by Dr. Kahn that contains data on patients who receive their medical care at the Positive Health Practice at SFGH. Dr. Kahn's research program has the enthusiastic support of his deuartment. the leadership of the AIDS Research Institute at UCSF and other nationally recognized clinical researchers.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24MH064384-02
Application #
6539323
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Gordon, Christopher M
Project Start
2001-07-25
Project End
2006-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
2
Fiscal Year
2002
Total Cost
$111,988
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Dowdy, David W; Geng, Elvin H; Christopoulos, Katerina A et al. (2011) Mortality among antiretroviral-eligible patients in an urban public clinic. J Acquir Immune Defic Syndr 57:297-300
Breban, Romulus; Napravnik, Sonia; Kahn, James et al. (2009) Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling. BMC Public Health 9 Suppl 1:S11
Kahn, James; Des Jarlais, Christine D; Dobkin, Loren et al. (2008) Mentoring the next generation of HIV prevention researchers: a model mentoring program at the University of California San Francisco and Gladstone Institute of Immunology and Virology Center for AIDS research. J Acquir Immune Defic Syndr 47 Suppl 1:S5-9
Roland, Michelle E; Neilands, Torsten B; Krone, Melissa R et al. (2005) Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 41:1507-13
Blower, Sally; Bodine, Erin; Kahn, James et al. (2005) The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 19:1-14
Pinkerton, Steven D; Martin, Jeffrey N; Roland, Michelle E et al. (2004) Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 18:2065-73
Martin, Jeffrey N; Roland, Michelle E; Neilands, Torsten B et al. (2004) Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 18:787-92
Barbour, Jason D; Hecht, Frederick M; Wrin, Terri et al. (2004) Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 190:251-6
Pinkerton, Steven D; Martin, Jeffrey N; Roland, Michelle E et al. (2004) Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 164:46-54
Jacobson, Mark A; Liu, Lea; Khayam-Bashi, Hassan et al. (2003) Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. AIDS 17:917-9

Showing the most recent 10 out of 11 publications